Sobi - Swedish Orphan Biovitrum AB (publ)

Sobi, also known as Swedish Orphan Biovitrum AB (publ), is a pharmaceutical company that specializes in the development and commercialization of innovative therapies for rare diseases and medical conditions with unmet needs. The company focuses on late-stage candidates, aiming to bring these therapies to market and provide solutions for patients who often have limited treatment options. Recognizing the challenges in the pharmaceutical industry, Sobi actively works to mitigate development risks. It conducts thorough research, rigorous clinical trials, and collaborates with key stakeholders to ensure the safety, efficacy, and accessibility of its therapies. This commitment to innovation is evident in the company's robust pipeline of promising candidates, which are identified through its research and development efforts. Sobi invests in cutting-edge technologies and scientific advances to make a meaningful impact on the healthcare landscape. The company's dedication to its mission is showcased through its collection of stories, which highlight its values, achievements, and the individuals driving innovation and change within the organization. Located in Stockholm, Sweden, Sobi's head office provides a centralized location for its operations. The company can be contacted via email or phone, with its address at Tomtebodavägen 23A. As Sobi continues to advance its therapies and make strides in the field of rare diseases, it remains committed to improving patient outcomes and revolutionizing the way healthcare is delivered.